# Differentiating clinical characteristics between two subtypes of antiphosphatidylethanolamine

> **NIH NIH R21** · NORTHWESTERN UNIVERSITY · 2022 · $240,000

## Abstract

ABSTRACT
Antiphosphatidylethanolamine (aPE) autoantibodies are associated with clinical symptoms of antiphospholipid
syndrome (APS). However, the clinical significance of aPE remains to be fully established. In an effort to define
aPE, we discovered that aPE actually consists of two distinctive subtypes. This notion is based on our findings
that there are two types of aPE antibodies – cofactor-independent (aPEi) and cofactor-dependent (aPEd), which
have different antigens and pathogenic mechanisms. In the current effort, we will investigate the clinical
characteristics of aPE subtypes in a retrospective study by testing the hypothesis that aPEi and aPEd antibodies
have different associations with the clinical and laboratory criteria for APS. The new knowledge will help define
and differentiate the two subtypes of aPE, with potentially important implications on diagnosis and patient care.

## Key facts

- **NIH application ID:** 10510394
- **Project number:** 1R21AI171491-01
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Rosalind Ramsey-Goldman
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $240,000
- **Award type:** 1
- **Project period:** 2022-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10510394

## Citation

> US National Institutes of Health, RePORTER application 10510394, Differentiating clinical characteristics between two subtypes of antiphosphatidylethanolamine (1R21AI171491-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10510394. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*